Trimethylamine N-oxide
|
Basic information |
| Metabolite name | Trimethylamine N-oxide |
 | HMDB0000925 |
 |
C01104 |
 |
1145 |
| Synonyms | trimethylamine-N-oxide; |
| No. of studies | 30 |
|
Basic information |
| Metabolite name | Trimethylamine N-oxide |
| HMDB0000925 |
|
C01104 |
|
1145 |
| Synonyms | trimethylamine-N-oxide; |
| No. of studies | 30 |
|
Relationship between Trimethylamine N-oxide and depression (count: 30) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M017 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M056 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M059 | Type2 | Xiaoyaosan-treated depressed group 14-week vs. baseline | Plasma | Human | Down |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Down |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M102 | Type1 | moderate MDD group vs. control group | Urine | Human | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Down |
| Study M1044 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M116 | Type3 | ketamine group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Down |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + SJ group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M140 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + median dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + high dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + augmentation treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + low dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M614 | Type2 | CUMS + resistance training group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M739 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M748 | Type1 | short-day group vs. long-day group | Plasma | C57BL/6 J mouse | Down |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |